- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Silence Therapeutics PLC (SLN)
Silence Therapeutics PLC stock price live, this page displays NASDAQ SLN stock exchange data. View the SLN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Silence Therapeutics PLC real time stock price chart below.
What Is the Silence Therapeutics PLC Stock Price Today?
The Silence Therapeutics PLC stock price today is 5.29.
What Is the Stock Symbol for Silence Therapeutics PLC?
The stock symbol for Silence Therapeutics PLC is ""SLN.""
What Stock Exchange Does Silence Therapeutics PLC Trade On?
Silence Therapeutics PLC is listed and trades on the NASDAQ stock exchange.
Is Silence Therapeutics PLC a Good Stock to Buy?
Determining whether Silence Therapeutics PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SLN quote. (ISIN: US82686Q1013)
What Is the Silence Therapeutics PLC Stock Price Today?
The Silence Therapeutics PLC stock price today is 5.29.
What Is the Stock Symbol for Silence Therapeutics PLC?
The stock symbol for Silence Therapeutics PLC is ""SLN.""
What Stock Exchange Does Silence Therapeutics PLC Trade On?
Silence Therapeutics PLC is listed and trades on the NASDAQ stock exchange.
Is Silence Therapeutics PLC a Good Stock to Buy?
Determining whether Silence Therapeutics PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SLN quote. (ISIN: US82686Q1013)
NASDAQ
Currency in USD
5.29
+0.19(+3.65%)
Real-time Data·
Fair Value
An estimate of a Silence Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.91
5.29
52 wk Range
1.97
20.48
SLN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
SLN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Silence Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.915.29
52 wk Range
1.9720.48
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SLN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Silence Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
33.94
Upside
+541.56%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Silence Therapeutics PLC Company Profile
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Silence Therapeutics PLC SWOT Analysis
RNA Frontie | Explore Silence Therapeutics's position in RNA therapeutics, focusing on cardiovascular and hematological disorders with promising clinical results |
Zerlasiran's Potential | Delve into Zerlasiran's market opportunity, with analysts anticipating 50-100%+ stock upside upon partnership announcement |
Divesiran Breakthrough | Learn about Divesiran's impact on Polycythemia Vera treatment, reducing phlebotomy needs and garnering significant partnership interest |
Financial Outlook | Analysts project $30M revenue for 2024-2025, with price targets ranging from $67 to $75, despite current trading near 52-week low of $4.82 |
Silence Therapeutics PLC Earnings Call Summary for Q4/2024
- Revenue increased to $43.3M in 2024 from $31.6M in 2023, driven by strategic collaborations with AstraZeneca and Hanseo Pharma
- Net loss reduced to $45.3M in 2024 from $54.2M in 2023; cash reserves of $147.3M extend runway into 2027
- Stock rose 5.24% premarket despite 81% decline over past year; analysts set price targets from $6 to $75
- Company plans to secure partner for Zolaciran Phase 3 study and complete Divisiran Phase 2 enrollment by year-end
- Management optimistic about ongoing partnership discussions and positive regulatory feedback for upcoming trials
Last Updated: 27/02/2025, 15:08
Read Full TranscriptCompare SLN to Peers and Sector
Metrics to compare | SLN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.0x | −2.0x | −0.6x | |
PEG Ratio | 0.08 | −0.09 | 0.00 | |
Price/Book | 2.6x | 2.0x | 2.6x | |
Price / LTM Sales | 8.9x | 7.9x | 3.3x | |
Upside (Analyst Target) | - | 309.9% | 39.1% | |
Fair Value Upside | Unlock | 15.9% | 5.4% | Unlock |
Analyst Ratings
6 Buy
0 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 33.94
(+541.56% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
-0.19 / -0.1323
Revenue / Forecast
224.00K / 6.93M
People Also Watch
FAQ
What Stock Exchange Does Silence Therapeutics Trade On?
Silence Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Silence Therapeutics?
The stock symbol for Silence Therapeutics is "SLN."
What Is the Silence Therapeutics Market Cap?
As of today, Silence Therapeutics market cap is 231.92M.
What Is Silence Therapeutics's Earnings Per Share (TTM)?
The Silence Therapeutics EPS (TTM) is -1.68.
When Is the Next Silence Therapeutics Earnings Date?
Silence Therapeutics will release its next earnings report on 17 Nov 2025.
From a Technical Analysis Perspective, Is SLN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Silence Therapeutics Stock Split?
Silence Therapeutics has split 0 times.
How Many Employees Does Silence Therapeutics Have?
Silence Therapeutics has 116 employees.
What is the current trading status of Silence Therapeutics (SLN)?
As of 29 Aug 2025, Silence Therapeutics (SLN) is trading at a price of 5.29, with a previous close of 5.10. The stock has fluctuated within a day range of 4.91 to 5.29, while its 52-week range spans from 1.97 to 20.48.
What Is Silence Therapeutics (SLN) Price Target According to Analysts?
The average 12-month price target for Silence Therapeutics is USD33.93857, with a high estimate of USD75 and a low estimate of USD4. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +541.56% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.